| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9312014 | Urology | 2005 | 5 Pages |
Abstract
Our experience has shown the good tolerability and potential efficacy of intravesical gemcitabine against recurrent transitional cell carcinoma of the bladder. Gemcitabine might be proposed, if our results are confirmed by larger studies, as a second-line therapy in patients who cannot tolerate more aggressive intravesical therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Vincenzo Serretta, Antonino Galuffo, Carlo Pavone, Rosalinda Allegro, Michele Pavone-MacAluso,